180 related articles for article (PubMed ID: 38319156)
21. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.
East JE; Sun W; Webb TJ
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308
[TBL] [Abstract][Full Text] [Related]
22. Discrete TCR Binding Kinetics Control Invariant NKT Cell Selection and Central Priming.
Cruz Tleugabulova M; Escalante NK; Deng S; Fieve S; Ereño-Orbea J; Savage PB; Julien JP; Mallevaey T
J Immunol; 2016 Nov; 197(10):3959-3969. PubMed ID: 27798168
[TBL] [Abstract][Full Text] [Related]
23. Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors.
Brigl M; van den Elzen P; Chen X; Meyers JH; Wu D; Wong CH; Reddington F; Illarianov PA; Besra GS; Brenner MB; Gumperz JE
J Immunol; 2006 Mar; 176(6):3625-34. PubMed ID: 16517731
[TBL] [Abstract][Full Text] [Related]
24. A humanized mouse model for
Saavedra-Avila NA; Dellabona P; Casorati G; Veerapen N; Besra GS; Howell AR; Porcelli SA
Front Immunol; 2022; 13():1011209. PubMed ID: 36263021
[TBL] [Abstract][Full Text] [Related]
25. Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop.
Matulis G; Sanderson JP; Lissin NM; Asparuhova MB; Bommineni GR; Schümperli D; Schmidt RR; Villiger PM; Jakobsen BK; Gadola SD
PLoS Biol; 2010 Jun; 8(6):e1000402. PubMed ID: 20585371
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for the recognition of C20:2-αGalCer by the invariant natural killer T cell receptor-like antibody L363.
Yu ED; Girardi E; Wang J; Mac TT; Yu KO; Van Calenbergh S; Porcelli SA; Zajonc DM
J Biol Chem; 2012 Jan; 287(2):1269-78. PubMed ID: 22110136
[TBL] [Abstract][Full Text] [Related]
27. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.
McCarthy C; Shepherd D; Fleire S; Stronge VS; Koch M; Illarionov PA; Bossi G; Salio M; Denkberg G; Reddington F; Tarlton A; Reddy BG; Schmidt RR; Reiter Y; Griffiths GM; van der Merwe PA; Besra GS; Jones EY; Batista FD; Cerundolo V
J Exp Med; 2007 May; 204(5):1131-44. PubMed ID: 17485514
[TBL] [Abstract][Full Text] [Related]
28. A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.
Wen X; Kim S; Xiong R; Li M; Lawrenczyk A; Huang X; Chen SY; Rao P; Besra GS; Dellabona P; Casorati G; Porcelli SA; Akbari O; Exley MA; Yuan W
J Immunol; 2015 Aug; 195(4):1459-69. PubMed ID: 26157173
[TBL] [Abstract][Full Text] [Related]
29. The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode.
Li Y; Girardi E; Wang J; Yu ED; Painter GF; Kronenberg M; Zajonc DM
J Exp Med; 2010 Oct; 207(11):2383-93. PubMed ID: 20921281
[TBL] [Abstract][Full Text] [Related]
30. Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates.
Yu KKQ; Wilburn DB; Hackney JA; Darrah PA; Foulds KE; James CA; Smith MT; Jing L; Seder RA; Roederer M; Koelle DM; Swanson WJ; Seshadri C
Immunogenetics; 2019 Jul; 71(7):465-478. PubMed ID: 31123763
[TBL] [Abstract][Full Text] [Related]
31. Effective functional maturation of invariant natural killer T cells is constrained by negative selection and T-cell antigen receptor affinity.
Bedel R; Berry R; Mallevaey T; Matsuda JL; Zhang J; Godfrey DI; Rossjohn J; Kappler JW; Marrack P; Gapin L
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E119-28. PubMed ID: 24344267
[TBL] [Abstract][Full Text] [Related]
32. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
33. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
[TBL] [Abstract][Full Text] [Related]
34. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
Takami M; Ihara F; Motohashi S
Front Immunol; 2018; 9():2021. PubMed ID: 30245690
[TBL] [Abstract][Full Text] [Related]
35. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
36. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
Wolf BJ; Choi JE; Exley MA
Front Immunol; 2018; 9():384. PubMed ID: 29559971
[TBL] [Abstract][Full Text] [Related]
37. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.
Li X; Shiratsuchi T; Chen G; Dellabona P; Casorati G; Franck RW; Tsuji M
J Immunol; 2009 Oct; 183(7):4415-21. PubMed ID: 19734232
[TBL] [Abstract][Full Text] [Related]
38. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
[TBL] [Abstract][Full Text] [Related]
39. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.
Delfanti G; Cortesi F; Perini A; Antonini G; Azzimonti L; de Lalla C; Garavaglia C; Squadrito ML; Fedeli M; Consonni M; Sesana S; Re F; Shen H; Dellabona P; Casorati G
Sci Immunol; 2022 Aug; 7(74):eabn6563. PubMed ID: 35984893
[TBL] [Abstract][Full Text] [Related]
40. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.
Iyoda T; Ushida M; Kimura Y; Minamino K; Hayuka A; Yokohata S; Ehara H; Inaba K
Int Immunol; 2010 Nov; 22(11):905-13. PubMed ID: 21118907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
